Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
NASDAQ:PGEN

Precigen Q3 2026 Earnings Date & Estimates

Precigen logo
$6.64 +0.56 (+9.21%)
Closing price 10/29/2026 04:00 PM Eastern
Extended Trading
$6.60 -0.04 (-0.60%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Precigen in Q3 2026

Precigen is expected to post earnings of $0.0589 per share on revenue of $71.56 million. In the same quarter a year earlier Precigen reported -$0.11 per share on revenue of $2.92 million. Precigen last reported on August 4, 2026, posting $0.05 per share and beating the -$0.0121 consensus estimate. Precigen has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0589
Expected Revenue
$71.56 million
Prior-Year EPS
-$0.11
Prior-Year Revenue
$2.92 million
Expected Revenue Growth
+2,348.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.05 (Beat by +$0.0621)
Last Quarter Revenue
$54.98 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Precigen Q3 2026 Earnings FAQ

Precigen (NASDAQ:PGEN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Precigen's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Precigen to post earnings of $0.0589 per share for Q3 2026.

The consensus revenue estimate for Precigen is $71.56 million for Q3 2026.

Precigen Earnings Headlines

Precigen (PGEN) Projected to Release Quarterly Earnings on Wednesday
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31167200
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
October 28 at 4:05 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/precigen-to-announce-third-quarter-2026-financial-results-and-provide-business-updates-on-november-4-302921419.html
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
 |  Weiss Ratings (Ad)
Critical Contrast: Fractyl Health (NASDAQ:GUTS) vs. Precigen (NASDAQ:PGEN)
October 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31146288
Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year Run
October 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/precigen-pgen-stock-may-fully-021313052.html
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pgen-vs-irwd-biotech-stock-150800736.html
See More Precigen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email.

About Precigen

Precigen (NASDAQ:PGEN) is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy. The company has also developed UltraCAR-T candidates, including PRGN-3006, for the treatment of certain cancers. Precigen evaluates its therapies through clinical trials and collaborations with academic and medical research organizations.

The company was formerly known as Intrexon Corporation and adopted the Precigen name in 2020 as it narrowed its focus toward human therapeutics. Precigen is headquartered in Germantown, Maryland. Its operations and clinical-development activities primarily serve the biotechnology and healthcare markets in the United States, while its research programs may involve international trial sites and collaborators. Helen Sabzevari, Ph.D., is the company’s president and chief executive officer.

View Precigen Profile
Earnings Tools